// App-Quantinova.ai

: Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Alexey V Danilov

Principal Investigators

  • Charles Herbaux

  • Martin J.S. Dyer

  • Peter Hillmen

  • Simon Rule

  • Ebenezer A Kio

  • Xi Huang

  • Siddhartha Mitra

  • Lionel Karlin

  • Christopher Fegan

Medical Centers

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Service des Maladies du Sang, CHU Lille, Lille, France

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Experimental Haematology, University of Leeds, Leeds, United Kingdom

  • Department of Haematology, Plymouth University Medical School, Plymouth, United Kingdom

  • Goshen Center for Cancer Care, Goshen, IN

  • Gilead Sciences, Inc., Foster City, CA

  • Pneumology Department, Lyon Sud University Hospital, Pierre Bénite, France

  • University Hospital of Wales, Cardiff, United Kingdom

Locations

  • United States

  • France

  • United Kingdom

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Entospletinib

  • Tirabrutinib

  • Idelalisib

Outcome

  • N/A

Study Design

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02457598

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved